Objective:To study the impact of the comprehensive pharmaceutical service on patients with extended prescription of chronic obstructive pulmonary disease(COPD)in the community.Methods:Eighty patients with COPD in extended prescription from January 2021 to March 2022 in Liantang Community Health Service Center were collected and the average age was 50-75 years old,among them,there 50 males and 30 females.They were divided into a control group with 40 cases and an intervention group with 40 cases according to whether they received pharmaceutical intervention at the time of medication administration,and the average age in the intervention group was(66.275±6.544)years,and the average disease course was(5.925±1.817)years;the average age of the control group was(67.175±5.913)years and the average disease course was(5.875±1.95)years.The intervention time was 6 months.After 6 months,the two groups were compared by questionnaires on medication compliance,disease awareness,and the correct use of inhalation devices and recording of adverse reactions were assessed.Results:The patients'knowledge about COPD disease,medication compliance,and correct operation of the drug inhalation device were improved after the intervention,and the incidence of adverse reactions decreased in the intervention group(P<0.05),and the difference was statistically significant(P<0.05).Conclusion:Pharmaceutical service intervention for patients with extended COPD prescriptions in the community reduces the incidence of adverse drug reactions,at the same time effectively improves patients'medication compliance and knowledge of the disease,and increases the correct use of inhalation devices.
chronic obstructive pulmonary diseaseextended community prescriptionpharmaceutical serviceinhalation devicecompliance
NETL
NSTL
万方数据
